We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 16, 2021

Benefit From Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer

European Urology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer
Eur Urol 2021 Aug 06;[EPub Ahead of Print], D Lorente, C Llacer, R Lozano, G de Velasco, N Romero-Laorden, M Rodrigo, Á Sánchez-Iglesias, C di Capua, E Castro, C Ferrer, A Sánchez-Hernández, D Olmos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading